Pharmacodynamics of abacavir in an in vitro hollow-fiber model system

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 2, 2002, Pages 464-470

  Drusano, G L ^a   Bilello, P A ^a   Symonds, W T ^a   Stein, D S ^a   McDowell, J ^a   Bye, A ^a   Bilello, J A ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALBUMIN; NUCLEOSIDE DERIVATIVE; OROSOMUCOID; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHRONOTHERAPY; CONTINUOUS INFUSION; DOSE CALCULATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG POTENCY; EXPERIMENTAL MODEL; HOLLOW FIBER; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS INHIBITION;

ANTI-HIV AGENTS; AREA UNDER CURVE; CELLS, CULTURED; COMPUTER SIMULATION; DIDEOXYNUCLEOSIDES; HIV-1; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING;

EID: 0036146636     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.2.464-470.2002     Document Type: Article

References (7)

1. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose ranging clinical studies
2. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro
3. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease
4. Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables
5. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
6. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
7. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model